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The Us3 protein kinase encoded by herpes simplex virus type-1 (HSV-1) suppresses apoptosis in infected cells and is sufficient to block
apoptosis induced by overexpression of Bad [Proc. Natl. Acad. Sci. 98 (2001) 10410]. While Us3 can induce phosphorylation of Bad,
phosphorylation of Bad is dispensable for Us3 anti-apoptotic function [J. Virol. 77 (2003) 6567]. We extend the findings with Bad to
demonstrate that Us3 blocks apoptosis induced by overexpression of Bid, a factor parallel to Bad in the apoptotic pathway, and Bax, a factor
downstream of Bad in the apoptotic pathway. A previous report suggested that Us3 exerts its effects at a premitochondrial stage [J. Virol. 75
(2001) 5491], but our results suggest that Us3 exerts anti-apoptotic effects downstream of the mitochondria. We show that the kinase activity
of Us3 is necessary for Us3 anti-apoptotic effects, because a catalytically inactive form of Us3 was unable to block apoptosis. A second
function of Us3, primary envelopment during viral egress, is conserved in the Us3 homologue of Pseudorabies virus (PRV) [J. Gen. Virol. 82
(2001) 2363]. Experiments published here demonstrate that PRV Us3 can also block apoptosis induced by Bax, suggesting that the anti-
apoptotic activity of Us3 is conserved across a-herpesviruses.
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seen in the clinic (Norfin and Thouvenot, 2003). To treatIntroduction
Herpes simplex virus type-1 (HSV-1) and herpes simplex
virus type-2 (HSV-2) are closely related viruses that are the
causative agents of fever blisters (commonly called ‘cold
sores’) and genital herpes infections. HSV infections are a
major cause of cornea scarring that can lead to blindness
and, in rare cases, lethal encephalitis. Approximately 80%
of the United States population has been exposed to HSV,
and 25% of the exposed individuals (approximately 20% of
the United States population) suffer recurrent reactivation of
the viruses. A number of therapeutic agents that target the
viral polymerase have proven effective for treating HSV
infections; however, drug-resistant strains are now being0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.10.019
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E-mail address: richard-roller@uiowa.edu (R.J. Roller).these resistant strains, additional therapeutic agents need to
be developed, preferably agents that target different viral
factors.
The Us3 gene is conserved among all members of the
a-herpesvirus family and possesses an easily recognizable
kinase domain (McGeoch and Davison, 1986). The ATP-
binding pocket and the catalytic lysine (also called the
invariant lysine) can be readily identified (Hanks et al.,
1988) and mutation of the invariant lysine to alanine
ablates Us3 kinase activity (Ryckman and Roller, in
press). Despite sequence differences in their N-termini,
the HSV-1 and Pseudorabies virus (PRV) Us3 proteins
possess a conserved function during envelopment of
progeny virus at the inner nuclear membrane (Klupp et
al., 2001; Reynolds et al., 2001). While not essential for
growth in cell culture (Purves et al., 1987), an HSV Us3
deletion virus (Us3-) is severely restricted for growth in
mice models (Asano et al., 1999, 2000), as is a PRV
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virulence of PRV Us3- in pigs was hypothesized to result
from defects in virus maturation (Wagenaar et al., 1995),
whereas the decreased growth of HSV Us3- in mice was
attributed to apoptosis of infected cells (Asano et al.,
1999, 2000). The necessity of HSV-1 Us3 for inhibition
of apoptosis in infected cells is well documented (Jerome
et al., 1999; Leopardi et al., 1997; Munger et al., 2001).
An anti-apoptotic activity of PRV Us3 has not been
reported.
Apoptosis is an active and ordered process by which a
cell eliminates itself from a population. Apoptosis is
important during embryogenesis, immune cell selection,
and in the elimination of damaged or infected cells.
Disruption of the apoptotic process is associated with
formation of birth defects, development of cancer, and
immune deficiencies. Many viruses, including HSV, pos-
sess genes that block apoptosis (reviewed in Koyama et
al., 2000). Inhibition of apoptosis is thought to help the
virus evade the cell-mediated immune response as well as
anti-viral activities induced within the infected cell. For
example, baculovirus-encoded IAP proteins inhibit cellu-
lar proteases (Bump et al., 1995; Xue and Horvitz, 1995)
called caspases that degrade cellular components during
apoptosis. Adenovirus (Chiou et al., 1994) and some
herpesviruses (Cheng et al., 1997; Marshall et al., 1999;
Nava et al., 1997) possess Bcl-2 homologues that block
apoptosis at the mitochondria before activation of the
caspases. Restoring the ability of an infected cell to
progress through apoptosis is an attractive means of
treating viral infections. The present study examines the
anti-apoptotic activity of HSV-1 and PRV Us3.
A family of pro-survival and pro-apoptotic members
called Bcl-2 family members are defined by distinct
protein domains that facilitate interactions between other
members of the Bcl-2 family. Pro-apoptotic family mem-
bers, such as Bax, Bid, and Bad, initiate apoptosis by
inducing release of cytochrome c and other factors from
the mitochondria (reviewed in Antonsson, 2001; Scorrano
and Korsmeyer, 2003). Pro-survival factors, such as Bcl-2,
antagonize the activity of pro-apoptotic factors by com-
plexing with and inactivating the pro-apoptotic factors
(reviewed in Antonsson, 2001; Scorrano and Korsmeyer,
2003). Bid and Bad are factors in parallel pathways that
induce apoptosis by modulating the activity of Bax or Bak,
factors that appear to directly mediate release of cyto-
chrome c from mitochondria. Proteolytic cleavage of Bid
or Bad stimulates their ability to activate Bax (or Bak), and
the activity of Bad can additionally be regulated by
phosphorylation of Bad on Ser-112 by RSK (Bonni et
al., 1999; Fang et al., 1999), Ser-136 by Akt (Datta et al.,
1997; Fang et al., 1999) (also called protein kinase B), and
Ser-155 by protein kinase A (Lizcano et al., 2000; Tan et
al., 2000; Virdee et al., 2000; Zhou et al., 2000). When
phosphorylated on Ser-112 and -136, Bad is inactive
because it is sequestered by 14-3-3 proteins (reviewed inTzivion et al., 2001). When dephosphorylated, Bad is
active and capable of interacting with Bcl-2, and this
competition for Bcl-2 effectively releases Bax from
Bax:Bcl-2 dimers and allows Bax to homodimerize and
disrupt the mitochondria (reviewed in Antonsson, 2001;
Scorrano and Korsmeyer, 2003). Bid appears to directly
bind Bax and induce an activating conformational change
in Bax that promotes Bax-mediated cell killing (Desagher
et al., 1999).
A previous report (Munger and Roizman, 2001)
demonstrated that Us3 is sufficient to block apoptosis
induced by overexpression of Bad. Inhibition of apo-
ptosis was correlated with phosphorylation of Bad on
Ser-112 and Ser-136—the two critical serines known to
be targeted by cellular kinases. More recently, phos-
phorylation of Bad at these two serines was shown to
be not essential for Us3 anti-apoptotic activity (Benetti
et al., 2003). The anti-apoptotic activity of Us3 corre-
lated with inhibition of proteolytic processing of Bad,
suggesting that Us3 may act on a caspase upstream of
Bad.
We confirm that Us3 can block apoptosis induced by a
non-phosphorylatable mutant of Bad and extend the find-
ings to demonstrate that Us3 is sufficient to block apopto-
sis induced by overexpression of Bid, a factor parallel to
Bad in the apoptotic pathway. Furthermore, Us3 was able
to block apoptosis induced by overexpression of Bax,
which demonstrates that Us3 can exert anti-apoptotic
effects downstream of Bad. A kinase inactive mutant of
Us3 was used to demonstrate that inhibition is dependent
upon Us3 catalytic activity. Lastly, we show that Us3 anti-
apoptotic activity may be conserved across a-herpesvi-
ruses, as PRV Us3 was also demonstrated to block
apoptosis induced by Bax.Results
Overexpression of pro-apoptotic Bcl-2 family members
caused a marked reduction in the number of
GFP-expressing cells
We adapted an assay for apoptosis that measures GFP
expression from an inducer plasmid (Schimmer et al.,
2001). Inducer plasmids contain sequences that direct the
expression of both a reporter gene (GFP) and an apo-
ptotic inducer (Bax, Bid, Bad, or a non-phosphorylatable
mutant of Bad [Bad-AA]). Apoptosis is measured as the
difference in the apparent transfection efficiency of in-
ducer plasmids to a GFP expression plasmid that lacks
inducers. Differences in the number of GFP-expressing
cells were evident by fluorescence microscopy in HEp-2
cells at 24 h (data not shown), at which point cells were
harvested and the percentage of GFP positive cells
quantified by flow cytometry. Within a given experimen-
tal trial, the data were normalized to cells transfected
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the inducer condition divided by the number of GFP
positive cells in the GFP condition. The ratios obtained
in any individual experimental trial were consistent with
ratios obtained in other experimental trials (P < 0.01). As
seen in Fig. 1, markedly fewer GFP positive cells were
observed when cells were transfected with inducer plas-
mids. While transfection with Bax or Bid reduced the
number of GFP-expressing cells by 50–60%, transfection
with Bad or Bad-AA (the non-phosphorylatable form of
Bad) reduced the number by about 30%. A similar
pattern in the number of GFP-expressing cells was
obtained using three independently prepared sets of
plasmid DNAs, suggesting that the differences are not
the result of variations in plasmid preparations.
Bcl-2 and Us3 partly restored the apparent transfection
efficiency in inducer conditions, whereas Us3-K220A and
B-gal did not
To confirm that the differences in the percentage of
GFP-expressing cells were the result of apoptosis and not
unrelated differences in transfection efficiency, Bcl-2 (a
factor that antagonizes the activity of Bax, Bid, or Bad)Fig. 1. Expression of Bax, Bid, Bad, or Bad-AA causes a decrease in
apparent transfection efficiency. Scale bar graph of relative numbers of
GFP-positive cells transfected with various inducer plasmids. Cultures of
HEp-2 cells (5 cm2) were transfected with Bax, Bid, Bad or Bad-AA, and
FL1 intensity of events corresponding to intact cells quantified by flow
cytometry. FL1 events were scored as ‘green’ if they fell in a gate set to
include only the brightest 0.5% of intact cells transfected with pcDNA. The
relative number of GFP-positive cells was determined by dividing the
percentage of green cells in the inducer conditions by the percentage of
green cells in the GFP condition (relative number of GFP positive cells =
inducer green%/GFP green%). Columns represent the mean, and error bars
represent the standard deviation of 5 (Bax and Bid) or 11 experiments (Bad
and Bad-AA).was cotransfected with the inducer plasmids. As seen in
Figs. 2A–D, coexpression of Bcl-2 efficiently increased
the number of GFP-expressing cells in the Bax, Bid, Bad,
and Bad-AA conditions. If rescue had been complete, the
column would have extended up to the dashed line. Cells
that were not rescued may have expressed Bcl-2 at
insufficient levels to protect or may have picked up the
inducer plasmid without picking up the rescue plasmid.
Expression of B-gal was included as a negative control,
because B-gal has never been reported to possess anti-
apoptotic activity. Coexpression of B-gal caused no sig-
nificant increase in the number of GFP-expressing cells in
any of the inducer conditions, demonstrating that rescue by
Bcl-2 is specific. We then tested the ability of wild-type
Us3 and of Us3-K220A, a kinase inactive form of Us3
(Ryckman and Roller, in press), to increase the number of
GFP-expressing cells. Us3 was as efficient at rescuing cells
from death as Bcl-2, whereas Us3-K220A was as efficient
as the negative control. This demonstrates that Us3 is able
to block apoptosis induced by a variety of Bcl-2 family
members and that the catalytic activity of Us3 is necessary
for this function. Furthermore, because Us3 rescues from
Bad-AA-mediated cell death, Us3-induced phosphorylation
of Bad at those residues is not necessary for Us3 inhibition
of apoptosis.
Indirect immunofluorescence revealed a large number of
cells with cleaved PARP in inducer conditions rescued with
empty vector, Us3-K220A and B-gal, but not Bcl-2 or Us3
We confirmed the results from our GFP assay with a
second apoptosis assay based on positive markers of
apoptosis. One late effect during apoptosis is caspase-
mediated cleavage of PARP, a DNA repair enzyme (Fig.
8, step 6a). Using an antibody that recognizes only the
cleaved form of PARP, we immunostained and examined
coverslips of HEp-2 cells transfected with various combi-
nations of inducer and rescue plasmids by microscopy.
High-powered magnification revealed brightly labeled
cells with a blebby apoptotic morphology on a back-
ground of lightly labeled cells with a healthy spindle-
shaped morphology (Fig. 3A). At a lower power, few
cells stained positive for cleaved PARP when cells were
transfected with a GFP expression construct (Fig. 3B),
but large numbers were observed when inducer plasmids
were cotransfected with pcDNA (Figs. 3C–F). We ob-
served a dramatic reduction in the number of labeled
cells per microscopic field when cells were cotransfected
with Bcl-2 (Figs. 3G–J) or Us3 (Figs. 3K–N), but not
Us3-K220A or B-gal (data not shown). The number of
brightly labeled cells was quantified as described in
Materials and methods and is represented in Figs. 4A–
D. Regardless of the inducer used, both Bcl-2 and Us3
reduced the number of brightly labeled cells by about
half, but the number of labeled cells in the Us3-K220A
and B-gal rescue conditions was comparable to the
Fig. 2. Expression of Bcl-2 or Us3 restores apparent transfection efficiency in Bax, Bid, Bad, or Bad-AA transfections. Scale bar graphs of relative
numbers of GFP-positive cells rescued with Bcl-2, Us3, Us3-K220A, or B-gal. Cultures of HEp-2 cells (5 cm2) were transfected with Bax (A), Bid (B),
Bad (C) or Bad-AA (D), and rescue plasmids. FL1 intensity and the percentage of green cells were quantified as in Fig. 1. The relative number of
GFP-positive cells was determined by dividing the percentage of green cells in the rescued conditions by the percentage of green cells in the vector-
rescued condition (relative number of GFP positive cells = rescue green%/vector green%). Columns represent the mean, and error bars represent the
standard error of 5 (Bax and Bid) or 11 experiments (Bad and Bad-AA). The dashed line represents the level of GFP-expressing cells expected if rescue
was complete. Student’s t test analysis demonstrated significance ( P < 0.01) of the differences between Bcl-2 or Us3 and vector or Us3-K220A.
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These results confirm that Us3 is capable of blocking
apoptosis induced by several different members of the
Bcl-2 family and, specifically, that the kinase activity of
Us3 is necessary for this inhibition and that phosphory-
lation of Bad at serines 112 and 136 is not necessary for
Us3 inhibition of apoptosis.Western blots demonstrate protein expression from the
inducer plasmids
Expression of the apoptotic inducers in the various
rescue conditions was demonstrated by Western blotting.
None of the inducers were detected in lysates of cells
transfected with a GFP expression construct, but inducers
Fig. 3. Pro-apoptotic Bcl-2 family members induce PARP cleavage that is blocked by Bcl-2 and Us3. Representative images of transfected cells stained for
cleaved PARP. Cultures of HEp-2 cells (5 cm2) grown on coverslips were transfected with Bax (panels C, G, and K), Bid (panels D, H, and L), Bad (panels E, I,
and M), or Bad-AA (panels F, J, and N) and pcDNA (panels C–F), Bcl-2 (panels G–J), or Us3 (panels K–N) or were transfected with only pcDNA (panel B).
Twelve hours after transfection, cells were fixed, washed, permeabilized/blocked overnight, labeled, and digital images taken at 200 magnification. Labeled
cells possess a morphology typical of apoptotic cells, as seen in the high magnification (630 oil) image (panel A).
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respective inducer plasmid (Figs. 5A–D). Each lane was
loaded with 50 Ag of protein and equal loading was
further demonstrated by Western blots for actin. Expres-
sion of apoptotic inducers was roughly equal between the
Bcl-2 and Us3 conditions, suggesting that Us3 does not
protect from apoptosis by inducing degradation or other-
wise altering expression of the pro-apoptotic Bcl-2 family
members.
Western blots demonstrate protein expression from the
rescue plasmids
Expression of Bcl-2, Us3, or Us3-K220A in the
various rescue conditions was demonstrated by Western
blotting. Rescue proteins were not detected in lysates of
cells transfected with GFP alone, but were observed in
lysates of cells transfected with the respective rescue
plasmid (Figs. 6A–C). Each lane was loaded with 50
Ag of protein and equal loading was further demonstratedby Western blots for actin. As seen in Fig. 6B, the Us3
polyclonal antibody reacted with one band from cell
lysates of uninfected cells. That band is observed in all
lysates tested, suggesting that the antibody reacts non-
specifically with a cellular protein. Three bands were
evident in lysates from HSV-infected cells: the nonspe-
cific band and two additional bands that correlate in size
with the specific doublet that Us3 separates as in SDS-
PAGE (Munger et al., 2001). A similar pattern was
observed in lysates of cells transfected with the Us3
rescue plasmid. As seen in Fig. 6C, Us3-K220A appears
to run as a single band in SDS-PAGE, above the
nonspecific band. The amount of Us3-K220A and Us3
expressed in transiently transfected cells appears similar,
suggesting that Us3-K220A is stable and accumulates to
levels comparable to that of Us3. This suggests that the
inability of Us3-K220A to rescue cells from apoptosis is
not the result of lower expression or stability of Us3-
K220A, but is the result the mutation in the kinase
domain.
Fig. 4. Cotransfection of Bcl-2 or Us3 with inducer plasmids decreases the number of cleaved PARP cells per confluent microscopic field. Scale bar graph of
the numbers of cells that stain positive for cleaved-PARP when inducer plasmids are cotransfected with various rescue plasmids. Cultures of HEp-2 cells
(5 cm2) grown on coverslips were transfected with Bax (A), Bid (B), Bad (C) or Bad-AA (D), and rescue plasmids and prepared for immunofluorescence
as in Fig. 3. The number of brightly labeled cells per confluent field was quantified as described in Materials and methods. Columns represent the mean,
and error bars represent the standard deviation of five experiments.
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Fig. 5. Western blots of apoptotic inducers in transient transfections.
Representative images of films obtained by chemiluminescent Western
blotting for Bax, Bid, Bad, and actin. Total protein (50 Ag) from lysates of
cells cotransfected with pRR1166 + pcDNA (lane 1), inducer + pcDNA
(lane 2), inducer + pRR1138 (lane 3), inducer + pRR1098 (lane 4), inducer +
pRR1203 (lane 5), or inducer + pCMVh (lane 6) were run on SDS-PAGE,
transferred onto nitrocellulose, and blocked with NFDM. Blots were probed
with anti-Bax (A), anti-Bid (B), anti-Bad (C and D), or anti-actin and
developed with chemiluminescent reagents.
Fig. 6. Western blots of rescue proteins in various conditions. Representative
images of films obtained by chemiluminescent Western blotting for Bcl-2,
Us3, and actin. Panel A: total protein (50 Ag) from lysates of cells
cotransfected with pRR1166 + pcDNA (lane 1), pRR1166 + pRR1138 (lane
2), pRR1187 + pRR1138 (lane 3), pRR1184 + pRR1138 (lane 4), pRR1179 +
pRR1138 (lane 5), or pRR1197 + pRR1138 (lane 6) were run on SDS-PAGE,
transferred to nitrocellulose, blocked with NFDM, probed with anti-Bcl-2 or
anti-actin antibodies, and developed with chemiluminescent reagents. Panel
B: total protein (50 Ag) from lysates of cells cotransfected with pRR1166 +
pcDNA (lane 1), pRR1187 + pRR1098 (lane 2), pRR1184 + pRR1098 (lane
3), pRR1179 + pRR1098 (lane 4), or pRR1197 + pRR1098 (lane 5), mock
infected (lane 6), or infected with HSV-1(F) (lane 7) were run on SDS-PAGE,
transferred to nitrocellulose, blocked with NFDM, probed with anti-Us3 or
anti-actin antibodies, and developed with chemiluminescent reagents. Panel
C: total protein (50 Ag) from lysates of cells cotransfected with pRR1166 +
pRR1098 (lane 1), pRR1166 + pcDNA (lane 2), pRR1166 + pRR1203
(lane 3), pRR1187 + pRR1203 (lane 4), pRR1184 + pRR1203 (lane 5),
pRR1179 + pRR1203 (lane 6), or pRR1197 + pRR1203 (lane 7), mock
infected (lane 8), or infected with HSV-1(F) (lane 9) were run on SDS-
PAGE, transferred to nitrocellulose, blocked with NFDM, probed with anti-
Us3 or anti-actin antibodies, and developed with chemiluminescent
reagents.
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from apoptosis
As represented in Fig. 7A, HSV-1 and PRV Us3 protein
sequence homology are restricted to the kinase domain. N-
terminal sequences appear unrelated, and the PRV N-termi-
nus is much shorter than the HSV-1 N-terminus. While both
proteins have been reported to affect viral egress from the
nucleus (Klupp et al., 2001; Reynolds et al., 2001), PRV
Us3 has not been reported to possess anti-apoptotic activity.
We were interested in determining if the N-terminal portion
of HSV-1 Us3 directed anti-apoptotic activity, or if the anti-
Fig. 7. Expression of PRV Us3 rescues the apparent transfection efficiency
in Bax transfections. (A) Schematic representation of the PRV and HSV-1
Us3 proteins. The Us3 protein sequence has been divided into three
portions; N-terminal regions of variable length, a kinase domain (shaded)
with 54% sequence similarity (40% identity), and short C-terminal regions.
(B) Scale bar graphs of relative numbers of GFP-positive cells rescued with
Bcl-2, PRV Us3, or B-gal. Cultures of HEp-2 cells (5 cm2) were
cotransfected with Bax and various combinations of rescue plasmids.
Relative numbers of GFP-positive cells were determined as in Fig. 2.
Columns represent the mean and error bars represent the standard deviation
of five experiments. Student’s t test analysis demonstrated significance ( P <
0.002) of the differences between Bcl-2, HSV-1 Us3 or PRV Us3, and
vector or B-gal.
 
Fig. 8. Schematic of relevant apoptotic events. Three parallel pathways
(steps 1a, 1b and 1c) are able to disrupt Bcl-2:Bax dimers to promote Bax-
induced release of cytochrome c (step 3) from the mitochondria to the
cytoplasm. Once in the cytoplasm, cytochrome c interacts with APAF-1 to
form a complex that activates caspase-9 (step 4). Caspase-9, an initiator
caspase, cleaves caspase-3 to an active form (step 5). Once active, caspase-
3 degrades numerous cellular factors to mediate a multitude of apoptotic
effects (step 6a), including translation inhibition (cleavage of eIF4G), shut-
down of DNA repair (cleavage of PARP), degradation of genomic DNA
(indirectly by cleaving DFF/ICAD), and activation of Bad and/or Bid in a
positive feedback loop (step 6b) that further promotes apoptosis. Us3 may
block programmed cell death at two points in the apoptotic pathway
(shaded boxes).
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ruses. The ability of the PRV Us3 to rescue cells from Bax-
induced apoptosis was measured in the GFP assay. FLAG-
tagged versions of both PRV and HSV-1 Us3 were cloned
and coexpressed with the Bax inducer plasmid. The FLAG-
tag did not appear to hinder HSV-1 Us3 anti-apoptotic
activity, as HSV-1 Us3-FLAG was as efficient at rescuing
cells from death as Bcl-2. Because PRV Us3 was as efficient
as HSV Us3 and Bcl-2 at rescuing cells from death, we
conclude (i) that the unique N-terminal sequences of HSV-1
Us3 do not specifically direct HSV-1 Us3 anti-apoptotic
activity and (ii) that Us3 anti-apoptotic activity is conserved
in PRV.Discussion
A schematic depicting the relevant steps in the apoptotic
pathway is shown in Fig. 8. Because Us3 inhibition of
apoptosis is not dependent upon phosphorylation of Bad
(Benetti et al., 2003) (Fig. 8, step 1a), we considered the
possibility that Us3 inhibition of apoptosis was independent
of Us3 kinase activity altogether. In such a model, Us3
would function similar to Bcl-2 or an IAP and block
apoptosis by binding to and inactivating pro-apoptotic
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of Us3-K220A, a kinase inactive form of Us3, to rescue
cells from apoptosis induced by overexpression of Bcl-2
family members. Critical amino acids in the kinase domain
of Us3 can easily be identified by sequence alignment with
other serine/threonine kinases (reviewed in Hanks et al.,
1988). Mutation of the invariant lysine to alanine is known
to ablate the activity of serine/threonine kinases and was
also effective at eliminating Us3 catalytic activity (Ryckman
and Roller, in press). Experiments with Us3-K220A dem-
onstrated that the kinase activity of Us3 is required for anti-
apoptotic function.
We note seemingly disparate results in the ability of
Bad and Bad-AA to induce apoptosis between the GFP
assay and the PARP assay. The two assays are categor-
ically different in that the GFP assay measures an
endpoint of accumulated cells lost and the PARP assay
measures the number of cells undergoing apoptosis in a
population at a particular moment in time. One explana-
tion for the seemingly disparate results could be that
apoptosis induced by Bax or Bid proceeds rapidly,
whereas apoptosis proceeds relatively slowly when in-
duced by Bad. In such a case, fewer cells would be
captured in the process of apoptosis at any given time in
Bax- or Bid-induced conditions than would be captured in
Bad-induced conditions.
An extensive body of literature has demonstrated that the
HSV Us3 is necessary for inhibition of apoptosis in infected
cells. Inhibition of apoptosis was found to occur at a
premitochondrial stage (Munger et al., 2001) (Fig. 8, steps
1 or 2). A 2001 report demonstrated that Us3 was sufficient
to block apoptosis induced by overexpression of Bad
(Munger and Roizman, 2001). Inhibition of apoptosis
correlated with phosphorylation of Bad on two critical
serines, suggesting that Us3 exerted its anti-apoptotic
effects by inhibiting Bad activity (Fig. 8, step 1a). A more
recent publication by the same group demonstrated that Us3
blocked apoptosis induced by overexpression of a non-
phosphorylatable mutant of Bad (Benetti et al., 2003).
Proteolytic processing of Bad was inhibited by Us3, sug-
gesting that Us3 may act on caspases at a point upstream of
Bad in the apoptotic pathway (Fig. 8, step 6b). In this
publication, we confirm that Us3 can block apoptosis
induced by overexpression of Bad or a non-phosphorylat-
able form of Bad (Bad-AA), and further demonstrate that
Us3 can block apoptosis induced by overexpression of Bid
(a factor parallel to Bad in the apoptotic pathway) and Bax
(a factor downstream of Bad in the apoptotic pathway). Our
data suggest that Us3 may block caspase activity at a point
downstream of mitochondrial events (Fig. 8, steps 3, 4, 5, or
6). Because caspase-3, a factor downstream of Bax, has
been shown to cleave pro-apoptotic Bad in a feedback loop
(Condorelli et al., 2001) (Fig. 8, step 6b), the previously
reported anti-apoptotic activities of Us3 upstream of Bad
may actually be the result of Us3 activities downstream of
Bax. We can rule out an alternate hypothesis that Us3blocks apoptosis by inducing degradation of Bax, Bid, or
Bad because Western blots demonstrated roughly equal
expression of inducer genes between the Bcl-2 and Us3
conditions.
While phosphorylation of Bad is not necessary for Us3
inhibition of apoptosis, Us3 induction of Bad phosphoryla-
tion may be one of multiple protective effects. The optimal
consensus sequence targeted by the Pseudorabies virus
(PRV) Us3 homologue has been defined as RRRXS/TZ,
where X is any amino acid and Z is not an acidic amino acid
(Purves et al., 1986). An increase in the number of spacer
amino acids between the arginines and the serine did not
dramatically affect affinity for the target if the target
contained three arginines (Leader et al., 1991). A 25-fold
decrease in affinity for substrate was observed if the
substrate possessed only two arginines, and a further three-
fold decrease was observed if such substrates have an
additional spacer amino acid between the arginines and
the serine. The HSV-1 Us3 has been demonstrated to behave
similar to the PRV homologue (Purves et al., 1986). We
have grouped potential phosphorylation sites in apoptotic
regulators according to their similarity to the PRV consen-
sus, where we define an optimal Us3 consensus as RRRXS/
TZ, RRRXXS/TZ, or RRRXXXS/TZ, a moderate consen-
sus as RRXS/TZ or RRXXS/TZ, and sequences without
upstream arginines as not substrates. By our definitions, Ser-
112 and Ser-136 of Bad fall within moderate Us3 consensus
sequences (Table 1) and may be direct targets of Us3.
During HSV infection, Us3 may phosphorylate Bad to block
apoptosis at a premitochondrial stage (Fig. 8, steps 1 and 2)
in addition to a factor downstream of Bax (Fig. 8, steps 3, 4,
5, or 6) as a redundant anti-apoptotic effect. Interestingly,
the consensus sequence recognized by Us3 is similar to the
consensus recognized by Akt (RXRXXS/TO, where X is
any amino acid and O is a bulky hydrophobic amino acid)
(Alessi et al., 1996). Akt has been shown to phosphorylate a
large number of factors to promote cell survival, including
Bad, caspase-9, forkhead transcription factors, and InB
kinase. Us3 could promote cell survival by directly targeting
some of these factors or, alternatively, by inducing Akt
activity. In addition to Akt targets, several other apoptotic
regulators have been demonstrated to have their activity
modulated by phosphorylation. We have examined the
sequence of Bax, Bid and sixteen other apoptotic regulators
previously shown to be phosphorylated (see Table 1) for the
presence of a Us3 consensus sequence. Neither Bax nor Bid
possess a serine or threonine in a Us3 consensus sequence;
however, a strong Us3 consensus was observed around Ser-
196 of caspase-9. Akt phosphorylation of Ser-196 inacti-
vates caspase-9 (Cardone et al., 1998), and phosphorylation
of caspase-9 (by Us3 directly or by Us3-induced Akt
activity) could be a single event responsible for our down-
stream and the previously reported upstream anti-apoptotic
effects of Us3. Caspase-9 is downstream of Bax in the
apoptotic pathway, but upstream of caspase-3, which has
been shown to cleave Bad (Condorelli et al., 2001) (Fig. 8,
Table 1
Examination of known and putative phosphorylation sites in apoptotic
regulators
Gene Target aaa Relevant sequencea Kinase Cons Strb
AFX Thr-28 SRPRSCTW Akt +
Ser-196 PRRRAASM Akt +++
Ser-250 SRNREESD Akt? notc
Ser-262 FRPRSSSN Akt +
Akt Thr-308 MKTFCGTP PDK1 not
Ser-473 PHFPQFSY Akt not
Atm Ser-2141 LRDREFST none +
Thr-2584 ARRSRITK none +
Thr-2751 TRKRKLTI none +
Bad Ser-112 TRSRHSSY Akt +
RSK
Ser-136 FRGRSRSA Akt +
Ser-155 RELRRMSD PKA notc
Baxd noned noned none notd
Bid Thr-59 GYDELQTD Casein not
Bcl-xL Ser-62 SWHLADSP AKK1 not
JNK1
Ser-106 RYRRAFSD none notc
Bcl-2 Ser-70 DPVARTSP PKC not
cdc2
Casp-9 Ser-196 LRRRFSSL Akt +++
DAP-K Ser-52 KKRRTKSS none +
Ser-58 SSRRGVSR none +
Ser-308 RKKWKQSV DAP-K not
Thr-680 ARLRKDTH none +
Ser-736 RRRPRLSS none +++
Thr-1081 HYRGRYTV none +
Ser-1334 LTRRKLSR none +
FKHR Thr-24 PRPRSCTW Akt +
Ser-256 PRRRAASM Akt +++
Ser-324 FRPRTSSN Akt +
FKHRL1 Thr-32 SRPRSCTW Akt +
Ser-257 PRRRAVSM Akt +++
Ser-320 FRSRTNSN Akt +
GSK-3-b Ser-9 GRARTSSF Akt +
IkB-a Ser-32 LDDRHDSG IKK-a not
Ser-36 HDSGLDSM IKK-a not
IKK-a Thr-23 MRERLGTG Akt +
Ser-176 KDVDQGSL Nik not
PFK-2 Ser-469 VRMRRNSF Akt + or
+++
Ser-486 RRPRNYSV Akt + or
+++
PI3-Kd noned noned none notd
p53d noned noned none notd
a Target amino acids and relevant sequences were obtained from NCBI and
the numbering may vary slightly from other publications.
b Strong Us3 consensus (RRRXSZ, RRRXXSZ, or RRRXXXSZ) is noted
as +++, moderate Us3 (RRXSZ or RRXXSZ) is noted as +, and serines
lacking upstream arginines are noted as not Us3 targets.
c An acidic residue downstream of the serine precludes this from being a
moderate Us3 consensus.
d These proteins do not possess serines or threonines in a Us3 consensus.
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Ser-196 phosphorylation are presently underway.
The a-herpesvirus family can be subdivided into the
Simplex and Varicello genera based on molecular criteria
and sequence analysis (McGeoch and Cook, 1994; Roiz-man et al., 1992). Us3 proteins in both genera have been
reported to possess a conserved function in primary
envelopment (Klupp et al., 2001; Reynolds et al.,
2001). Anti-apoptotic activity has been ascribed to Us3
in HSV-1 and HSV-2 of the Simplexviruses, but such an
activity has not been identified for Us3 in a member of
the Varicelloviruses. PRV Us3 was selected as a repre-
sentative Varicellovirus to determine if the anti-apoptotic
activity of Us3 is conserved between a-herpesvirus
genera. Because sequence homology between PRV and
HSV-1 Us3 is restricted to the kinase domain, we were
also able to determine if the nonconserved N-terminal
portion of HSV-1 Us3 directed Us3 anti-apoptotic activity.
Our results demonstrated that PRV Us3 was as efficient
as HSV-1 Us3 at rescuing cells from apoptosis induced
by Bax, suggesting that the anti-apoptotic activity of Us3
is conserved among a-herpesvirus family members. Ad-
ditionally, the N-terminal sequences of HSV-1 Us3 not
shared with PRV Us3 are not uniquely required for
prevention of Bax-induced apoptosis.
The efficacy of delivering of pro-survival genes, such as
Bcl-2, as therapeutic treatment after ischemia (Zhao et al.,
2003) or for diseases such as Alzheimer’s (Maguir-Zeis et
al., 2001) is being tested. Us3 is a promising therapeutic
anti-apoptotic factor, because although Bcl-2 is required in
stoichiometric amounts, Us3 anti-apoptotic activity is cat-
alytic and, presumably, small amounts of Us3 would need
to be expressed or delivered. An additional advantage of
Us3 over Bcl-2 is that Us3 kinase activity can be inhibited
with xanthate derivatives (Walro and Rosenthal, 1997),
suggesting that Us3 activity could be modulated after gene
delivery if anti-Us3 drugs with low toxicity can be
identified.
A number of nucleotide analogs that target the viral
polymerase have been effectively used to treat HSV in the
clinic. HSV strains resistant to existing drug treatments are
appearing, and new therapies are needed that will target a
different portion of the viral lifecycle (Norfin and Thouve-
not, 2003). Drugs that inhibit Us3 activity could be useful
for treating HSV infections, because a Us3 deletion virus
was less virulent and propagated less efficiently than a WT
virus in mice (Asano et al., 2000; Asano et al., 1999).
Identification of Us3 interacting partners and mapping of the
interacting domains may allow for the design of drugs that
specifically inhibit Us3.Materials and methods
Cell culture
HEp-2 cells, originally obtained from ATCC, were main-
tained in growth media consisting of DMEM (GibcoBRL) +
5% FCS (GibcoBRL) + 100 U/ml Pen and 100 Ag/ml Strep
(GibcoBRL). Cells were carried for no more than 15
passages.
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To create the GFP expression construct (pRR1166), EGFP
was PCR amplified (left-GGAAGGCGCCACGTTAAC-
CATGGTGAGCAAGGGC right-ATATCGGTCCGTT-
TAAACCGGTTACTTGTACAGCTCGTCC) from
pIRESpuro-EGFP (ClonTech), digested with SfoI and RsrII,
and ligated into the approximately 4700-bp fragment of RsrII
and BsaBI digested pcDNAIII (Invitrogen). This removed
most of the neomycin resistance gene and placed EGFP under
control of the sv40 promoter, although leaving the multi-
cloning site (MCS) available for subsequent use. Bax,
HA:Bad, and HA:Bad-AA (Zha et al., 1996) were cloned
into the EcoRI site of the pRR1166 MCS by digesting the
Korsmeyer pSFFV plasmids with EcoRI to create the inducer
plasmids pRR1187, pRR1179, and pRR1197, respectively. A
frameshift in the coding sequence of our pSFFV Bid plasmid
(Wang et al., 1996) was corrected by PCR amplification (left-
GCTGGAATTCTGATGGACTGTG right-TGCAGAATT-
CAGTCCATCCCATT). The PCR product was digested with
EcoRI and cloned into the EcoRI site of pRR1166 to create
the inducer plasmid pRR1184. The Bcl-2 expression con-
struct was created by digesting the Bcl-2 pSFFV plasmid
(Hockenbery et al., 1990) with EcoRI and cloning into the
EcoRI site of pcDNAIII to create pRR1138. pRR1098, the
Us3 expression construct, is described elsewhere (Reynolds
et al., 2001). Plasmid pRR1203 encodes a mutant Us3, in
which lysine 220 is mutated to alanine (Us3-K220A) and has
been described elsewhere (Ryckman and Roller, in press).
The FLAG-tagged Us3 expression construct, pRR1206, was
created by PCR amplification from pRR1098 (left-GATC-
GAATTCGCGAATGGCCTGTCGTAAGT r igh t -
GCGGTCTAGATCATTTATCATCATCATCCTTA-
TAGTCTTTCTGTTGAAACAGCGGCA), digestion with
EcoRI and XbaI, and ligation into EcoRI and XbaI digested
pcDNAIII. The PRV FLAG-tagged Us3 expression con-
struct, pRR1207, was created by PCR amplification from
PRV(Ka) ( l e f t -GATCGAATTCAACAATGGCC-
GACGCCGGAAT right-GATCTCTAGATTATTTATCAT-
CATCATCCTTATAGTCTACGGTCCACATTCCAAAGT),
digestion with EcoRI and XbaI, and ligation into EcoRI and
XbaI digested pcDNAIII. h-galactosidase (B-gal) was
expressed from pCMVh (ClonTech).
Transfections
Transfection efficiencies of 25–50% were routinely
obtained with 1.0 Ag of plasmid (0.2 Ag inducer and 0.8
Ag rescue) and 5 Al LipofectAMINE Reagent (Invitrogen)
per well of a 12-well dish (4.5 cm2) of HEp-2 cells. Briefly,
1.0 Al of DNA was added to 34 Al of DMEM, and 5 Al of
LipofectAMINE was added to 30 Al of DMEM. These DNA
and LipofectAMINE solutions were combined, vortexed
briefly, and 300 Al of DMEM added promptly. Within 5
min, the resultant, approximately 375-Al solution, was
added to a single well of DMEM-washed HEp-2 cells(70% confluent) and incubated for 60 min at 37 jC. The
cells were washed once with supplemented growth media
(DMEM + 10% FBS + Pen/Strep) and the cells were
incubated in supplemented growth media for 24 h at 37 jC.
For transfections in 6 wells, the amounts and volumes of the
reagents were doubled. Please note that the incubation times
in our optimized transfection procedure differ from those
recommended by the manufacturer.
Cell harvesting
For flow cytometry, 24 h after transfection, cells were
harvested with trypsin, added back to the growth media and
then centrifuged at 6000 rpm (3000  g) at room temper-
ature (RT) for 4 min. Cells were washed twice with PBS and
finally resuspended in 200-Al PBS. Intensity of the GFP
fluorescence of intact cells was recorded using the Cell-
Quest Pro software package (Becton Dickinson, Inc.) on a
FACSCaliber (Becton Dickinson, Inc.) and analyzed with
the FloJo version 3.4 software package (Tree Star, Inc.).
For Western Blotting, 18 h after transfection, cells were
scraped from the dish in the growth media and then
centrifuged at 6000 rpm (3000  g) at RT for 4 min. Cells
were washed once with PBS before 88 Al of WCE Buffer
(20 mM HEPES, pH 7.2; 0.5% NP-40; 5 mM EDTA; 5 mM
EGTA; and 10 mM NaF) was added and cells were vortexed
twice at medium speed for 5–10 s. Cells were incubated on
ice for 5 min, 7 Al of 5 M NaCl was added, and cells were
incubated on ice for 30 min. The solution was then centri-
fuged at 14000 rpm (16000  g) for 10 min at 4 jC. The
supernatant was moved to a fresh tube and protein concen-
tration determined by Bradford Assay (Bio-Rad), according
to the manufacturers protocol.
Western blotting
Total protein (50 Ag) was run on each lane of a 15%
polyacrylamide gel (with a 6% stacking gel). After SDS-
PAGE, efficient transfer to a Protran nitrocellulose mem-
brane (Schleicher and Schuell) was checked with Ponceau S
(0.5% Ponceau S, 1% acetic acid) and the blot was then
blocked in T-TBS (20 mM Tris, pH 7.5, 150 mM NaCl,
0.05% Tween-20, 0.05% sodium azide) + 5% nonfat dried
milk (NFDM) overnight at RT. Blots were washed twice
with T-TBS, exposed to primary antibodies (in T-TBS) for
2+ h at RT, washed twice, exposed to secondary antibodies
(in T-TBS) for 1 h at RT, and washed 3 times. Blots were
then exposed to ECL reagents (Amersham-Pharmicia Bio-
tech) in the dark for 2 min and images obtained on Hyper-
film ECL (Amersham-Pharmicia Biotech).
Immunofluorescence
For immunofluorescence to detect cleaved PARP, 15
h after transfection, coverslips of HEp-2 cells were fixed
in 2% formaldehyde in PBS for 10 min. Cells were washed
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Buffer (0.5% Triton X-100, 0.5% sodium deoxycholate,
1.0% BSA, and 0.05% sodium azide in PBS). Coverslips
were then treated with 40 Al of primary stain (rabbit anti-
Cleaved PARP [Promega] diluted 1:400 in IF Buffer),
washed once with PBS, and then treated with 40 Al of
secondary stain (Texas Red-conjugated goat anti-Rabbit
[Molecular Probes] diluted 1:400 in IF Buffer). Coverslips
were washed twice with PBS, mounted onto glass slides,
and viewed on a BX-51 Light Microscope (Olympus, Inc.)
using a ‘Spot’ CCD Camera and software (Diagnostics
Instruments, Inc).
Quantification of PARP-positive cells
Digital images of microscopic fields were taken such that
brightly labeled apoptotic cells could clearly be discrimi-
nated from light background labeling of healthy cells and
lightly labeled healthy cells could clearly be discriminated
from dark regions where no cells existed. Using the histo-
gram feature of Adobe PhotoShop (Adobe, Inc), the pixels
in each digital image were scored as dark (no cells) or not
dark (consisting of both healthy and apoptotic cells) to
obtain a relative percent of cell confluence for each digital
image. The number of brightly labeled cells in a given
digital image was divided by the confluence of the cells in
that image to obtain the number of brightly labeled cells per
confluent monolayer for that digital image. Ten digital
images were examined for each rescue condition in five
replicate experiments.
Antibodies
The following primary antibodies were used in Western
Blotting at the indicated concentrations; Mouse anti-Bax
(Sigma, clone 6A7) was used at 10 Ag/ml, Rabbit anti-Bid
(Cell Signaling Technologies) was used at a 1:1000 dilution,
Rabbit anti-Bad (Cell Signaling Technologies) was used at a
1:1000 dilution, Rabbit anti-Us3 (a generous gift of Bernard
Roizman; Munger et al., 2001) was used at 1:1000, Hamster
anti-Bcl-2 (Pharmingen, clone 6C8) was used at 1:1000, and
Mouse anti-actin (Sigma, clone AP-40) was used at 1:1000.
HRP-secondary antibodies were used at 1:1000 dilution in
Western blotting; Sheep anti-Mouse (Amersham), Goat anti-
Rabbit (Santa Cruz Biotechnology), and Goat anti-Hamster
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